AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06112314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brenetafusp
Description: Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
Study NCT06112314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Concentrate for solution for infusion at a unit dose of 10 mg/mL.
Study NCT06112314 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Concentrate for solution for infusion at a unit dose of 10 mg/mL.
Study NCT06112314 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Relatlimab
Description: Concentrate for solution for infusion at a unit dose of 16 mg/mL.
Study NCT06287112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic transpapillary gallbladder drainage (ETGBD)
Description: Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
Study NCT04741880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered.
Study NCT04741880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered.
Study NCT06171399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Boost descriptor
Description: Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
Study NCT06171399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No descriptor (control)
Description: Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
Study NCT06197035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
Study NCT06443736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized perineal massage
Description: Patients in this arm will be educated in the perineal massage proposed by the authors; the training will be performed during a group session, (organized bimonthly) conducted by obstetrical staff specialists, in the presence of the principal investigator and/or co-authors. In these sessions, a brief lecture on aspects of primary prevention related to pelvic floor structures (healthy diet, body weight control, moderate physical activity avoiding excessive exertion, posture control, therapy minctional education) and then screened an explanatory video regarding the three-step perineal massage proposed by the authors. The adequately prepared patient should then apply such perineal massage at home from the 34th gestational week until delivery according to the procedural methods provided.
Study NCT06443736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary prevention
Description: Patients in this arm will be offered a group meeting in which aspects of primary prevention related to the structures of the pelvic floor (healthy diet, body weight control, moderate physical activity avoiding exertion excessive exertion, posture control, micturition educational therapy); participation in this meeting will be on a voluntary basis, and patients randomized to that group will have free choice in educating the pelvic floor pelvic floor in pregnancy.
Study NCT06347146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy Training (FLT) workshops
Description: Adolescents and youths and their caregivers will receive six 1-2 hour workshop sessions that cover components on saving, and financial management. The sessions will: introduce participants to saving, saving strategies, career planning, and the utilization of financial institutions, including saving in banks.
Study NCT06347146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: Each adolescent and youth will have a mentor who will visit with them monthly for the duration of the intervention. The one-to-one mentorship program is intended to help AYaAIDS overcome a variety of challenges they face in daily life by fostering meaningful and lasting relationships with near peer or adult role models. Resilience theory posits that having a supportive adult outside the family reduces the impact of stress on AY's mental health. Mentors will be high school students who will be trained by the schools or NGO staff depending on study condition. All mentors will be reimbursed for their transport expenses to the field, plus an equivalent of a $5 gift card for airtime per visit.
Study NCT06347146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Income Generation Activity (IGA)
Description: Participants will be trained on investing in income-generating activities (IGA) during the FLT workshops and will be allowed to use up to 30% of their matched savings to invest in an IGA intended to benefit the adolescent and youth (AY) and their caregiving families. The IGA portion is intended to promote economic stability.
Study NCT06347146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Development Accounts (YDA)
Description: Each adolescent and youth (AY) will receive a youth development account, which is a matched savings account held in the AY's name in a financial institution under the Central Bank (Bank of Uganda). Any of the AY's family members, relatives, or friends is encouraged to contribute towards the YDA. The account is then matched with money from the program. The match cap (maximum family contribution to be matched by the program) will be an equivalent of US$10 a month per family or US$200 for the 20-months intervention period. AY who save the maximum amount will have $600 ($200 plus $400 in match-a 2:1 match rate).
Study NCT05977088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetetive Transcranial Magnetic Stimulation
Description: .Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group.
Study NCT05977088 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetetive Transcranial Magnetic Stimulation
Description: .Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group.
Study NCT04780464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
Study NCT04780464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
Study NCT04780464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Oral Product
Description: 100 mg BD on day 1 to day 7 of each 14 day cycle until PD
Study NCT04780464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD
Study NCT04780464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
Study NCT06169111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGulatory T cells in Autism induced by maternal Immune activation
Description: REGulatory T cells in Autism induced by maternal Immune activation
Study NCT06169111 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGulatory T cells in Autism induced by maternal Immune activation
Description: REGulatory T cells in Autism induced by maternal Immune activation
Study NCT06254053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zirconia reinforced glass ionomer
Description: Restorative material
Study NCT06254053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass ionomer cement
Description: Restorative material
Study NCT05712408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 800g Challenge
Description: The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
Study NCT06266455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Fortification
Description: Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz
Study NCT06266455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Fortification
Description: Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz
Study NCT06266455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adjustable Fortification
Description: Additional liquid protein supplementation to maintain serum BUN levels within goal range (9-14mmol/dL)
Study NCT06266455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adjustable Fortification
Description: Additional liquid protein and/or MCT oil supplementation to maintain protein, fat, and energy intake within goal range based upon mid-infrared human milk analysis
Study NCT05981560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A - Closed Chain Exercise
Description: 17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks
Study NCT05981560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B - Neuromuscular Training Exercise
Description: 17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
Study NCT05018390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
Study NCT05018390 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Osteopathic manipulative treatment
Description: Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
Study NCT06401382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A modified aligner appliance with NiTi springs
Description: The modified aligner appliance will be used until the final position is achieved.
Study NCT06401382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fixed appliances
Description: The traditional fixed appliances with a standard prescription will be used.
Study NCT06384833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days
Study NCT06384833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: NAC (effervescent) 600mg 1 tab PO OD for 45 days
Study NCT06384833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pharmacologically inactive substance
Study NCT05602324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lauric Acid and Berberine
Description: intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
Study NCT04952350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
Study NCT04952350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
Study NCT05748587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Iron
Description: Serum iron levels in study groups
Study NCT05748587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RBCs Alpha-synuclein
Description: α-syn levels in RBCs
Study NCT05748587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Soluble lymphocyte activation gene
Description: sLAG-3 in the serum of study groups
Study NCT05748587 — intervention group
Intervention type: RADIATION
Intervention: Brain computed tomography
Description: Brain CT of patients after admission
Study NCT05748587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Iron
Description: Iron in brain homogenate of rats
Study NCT05748587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Alpha-synuclein
Description: α-syn expression in rat's brain
Study NCT05748587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain lymphocyte activation gene
Description: LAG-3 expression in rat's brain
Study NCT05245474 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)
Description: Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
Study NCT05748587 — intervention group
Intervention type: DRUG
Intervention: Deferoxamine
Description: intramuscular deferoxamine (200 mg/kg) injection to rats
Study NCT04603326 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids
Study NCT05001646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-home resonance-based electromagnetic field protection device
Description: Participants will have an in-home EMF protection device
Study NCT05245474 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)
Description: Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
Study NCT05607147 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Testing for SARS CoV2 Antigen and Antibody
Description: Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
Study NCT05845983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Description: Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
Study NCT05845983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
Study NCT04811482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCIT-CALM (Teacher-Child Interaction Training-CALM)
Description: This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
Study NCT04965532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane anesthesia
Description: Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
Study NCT04965532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane anesthesia
Description: Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
Study NCT04965532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
Study NCT04886791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal NOTES hysterectomy
Description: Vaginal assited NOTES hysterectomy
Study NCT04886791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy
Description: Vaginal hysterectomy
Study NCT05018663 — intervention group
Intervention type: OTHER
Intervention: Artificial Intelligence software ROSE
Description: Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
Study NCT05545189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy,polypectomy
Description: polyp removal during colonoscopy
Study NCT05053035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL001
Description: Administered via intravenous (IV) infusion
Study NCT05053035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via intravenous (IV) infusion